Use of functional assays to detect and quantify functional selectivity

Drug Discovery Today: Technologies

Volumn 7, Issue 1, 2010, Pages

  Clarke, William P ^a   Berg, Kelly A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA ARRESTIN; ION CHANNEL; LIGAND; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; RECEPTOR BLOCKING AGENT;

AGONIST; ALLOSTERISM; ARTICLE; ASSAY; BINDING AFFINITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME ACTIVATION; FLUORESCENCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

EID: 78649903879     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.07.001     Document Type: Review

References (16)

1. R.F. Furchgott The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes N.J. Harper, A.B. Simmonds, Advances in Drug Research Vol. 3 1966 Academic Press 21 55
2. T.P. Kenakin, and D. Beek Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships J. Pharmacol. Exp. Ther. 213 1980 406 413
3. K.P. Hofmann A G protein-coupled receptor at work: the rhodopsin model Trends Biochem. Sci. 34 2009 540 552
4. J.W. Black, and P. Leff Operational models of pharmacological agonism Proc. R. Soc. Lond. B Biol. Sci. 220 1983 141 162
5. R.A. Cerione The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system Biochemistry 23 1984 4519 4525
6. T. Costa, and A. Herz Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins Proc. Natl. Acad. Sci. U.S.A. 86 1989 7321 7325
7. T.P. Kenakin Receptor conformational induction vs. selection: all part of the same energy landscape Trends Pharmacol. Sci. 17 1996 190 191
8. T. Kenakin Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J. 15 2001 598 611
9. T. Kenakin Functional selectivity through protean and biased agonism: who steers the ship? Mol. Pharmacol. 72 2007 1393 1401
10. T. Kenakin Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol. Sci. 16 1995 232 238
11. J.D. Urban Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320 2007 1 13
12. J.D. Violin, and R.J. Lefkowitz Beta-arrestin-biased ligands at seven-transmembrane receptors Trends Pharmacol. Sci. 28 2007 416 422
13. T. Kenakin Drug efficacy at G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 42 2002 349 379
14. P.R. Moya Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-HT2A and 5-HT2C receptors J. Pharmacol. Exp. Ther. 321 2007 1054 1061
15. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
16. T.P. Kenakin 7TM receptor allostery: putting numbers to shapeshifting proteins Trends Pharmacol. Sci. 30 2009 460 469